[{"id":"73c201a6-e02a-4259-b6f1-d64c285f2a0c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02301754","created_at":"2021-01-18T10:52:53.377Z","updated_at":"2024-07-02T16:37:02.457Z","phase":"Phase 1","brief_title":"INVAC-1 Anti-Cancer hTERT DNA Immunotherapy","source_id_and_acronym":"NCT02301754","lead_sponsor":"Invectys","biomarkers":" IFNG • IL6 • TNFA • CXCL8 • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • CXCL8 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INVAC-1"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2019-02-26"}]